Screener
Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities (current) of $154K in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) decreased by 51.4% year-over-year, from $317K to $154K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a -100.0% compound annual growth rate (CAGR), from $282K to $0.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude